文献速递MDS 与骨髓增殖性肿瘤白血病

芦可替尼诱导的DNA修复缺陷使骨髓增殖性肿瘤对PARP抑制剂敏感

Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms.
PubMed 文献 · Blood · 2017-10-17

表达JAK2(V617F)、MPL(W515L)或CALR(del52)的细胞系积累活性氧诱导的DNA双链断裂,对PARP抑制剂奥拉帕利和BMN673中度敏感,但原代MPN细胞样本敏感性差异大。芦可替尼抑制BRCA介导的同源重组和DNA依赖性蛋白激酶介导的非同源末端连接,与奥拉帕利联用导致毒性双链断裂大量积累,增强清除MPN原代细胞(包括多数患者的疾病起始细胞)。BMN673、芦可替尼和羟基脲三联在体内对JAK2(V617F)+小鼠MPN样疾病及JAK2(V617F)+、CALR(del52)+和MPL(W515L)+原代MPN异种移植有效。

要点

  • 表达JAK2(V617F)、MPL(W515L)或CALR(del52)的细胞系积累活性氧诱导的DNA双链断裂,对奥拉帕利和BMN673中度敏感。
  • 原代MPN细胞样本对PARP抑制剂的敏感性存在高度异质性。
  • 芦可替尼抑制BRCA介导的同源重组和DNA-PK介导的非同源末端连接,与奥拉帕利联用增强清除MPN原代细胞及多数患者的疾病起始细胞。

核心结论

  • 作者推测芦可替尼诱导的双链断裂修复通路缺陷使MPN细胞对PARP抑制剂触发的合成致死敏感。

研究设计与样本

  • 研究使用表达JAK2(V617F)、MPL(W515L)或CALR(del52)的细胞系、患者原代MPN细胞样本、JAK2(V617F)+小鼠MPN样疾病模型及JAK2(V617F)+、CALR(del52)+和MPL(W515L)+原代MPN异种移植模型。

主要发现

  • 表达JAK2(V617F)、MPL(W515L)或CALR(del52)的细胞系积累活性氧诱导的DNA双链断裂,对奥拉帕利和BMN673中度敏感。
  • 来自不同患者的原代MPN细胞样本对这些药物的敏感性呈现高度变异性。
  • 芦可替尼抑制BRCA介导的同源重组和DNA依赖性蛋白激酶介导的非同源末端连接两大双链断裂修复机制。
  • 芦可替尼与奥拉帕利联用导致毒性双链断裂大量积累,增强清除MPN原代细胞,包括多数患者的疾病起始细胞。
  • BMN673、芦可替尼和羟基脲三联在体内对JAK2(V617F)+小鼠MPN样疾病及JAK2(V617F)+、CALR(del52)+和MPL(W515L)+原代MPN异种移植高度有效。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myeloproliferative neoplasms (MPNs) often carry JAK2(V617F), MPL(W515L), or CALR(del52) mutations. Current treatment options for MPNs include cytoreduction by hydroxyurea and JAK1/2 inhibition by ruxolitinib, both of which are not curative. We show here that cell lines expressing JAK2(V617F), MPL(W515L), or CALR(del52) accumulated reactive oxygen species-induced DNA double-strand breaks (DSBs) and were modestly sensitive to poly-ADP-ribose polymerase (PARP) inhibitors olaparib and BMN673. At the same time, primary MPN cell samples from individual patients displayed a high degree of variability in sensitivity to these drugs. Ruxolitinib inhibited 2 major DSB repair mechanisms, BRCA-mediated homologous recombination and DNA-dependent protein kinase-mediated nonhomologous end-joining, and, when combined with olaparib, caused abundant accumulation of toxic DSBs resulting in enhanced elimination of MPN primary cells, including the disease-initiating cells from the majority of patients. Moreover, the combination of BMN673, ruxolitinib, and hydroxyurea was highly effective in vivo against JAK2(V617F)+ murine MPN-like disease and also against JAK2(V617F)+, CALR(del52)+, and MPL(W515L)+ primary MPN xenografts. In conclusion, we postulate that ruxolitinib-induced deficiencies in DSB repair pathways sensitized MPN cells to synthetic lethality triggered by PARP inhibitors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Nieborowska-Skorska M, Maifrede S, Dasgupta Y, et al. Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms. Blood. 2017. PMID: 29042365. doi:10.1182/blood-2017-05-784942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。